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Objective. To investigate whether single-nucleo-
tide polymorphisms (SNPs) within the genes PRF1,
GZMB, UNC13D, and Rab27a, which are involved in
natural killer cell dysfunction and known to contribute
to the risk of hemophagocytic lymphohistiocytosis
(HLH), confer an increased risk of susceptibility to
systemic-onset juvenile idiopathic arthritis (JIA).
Methods. Four SNPs across the PRF1 gene locus,
5 for GZMB, 7 for UNC13D, and 11 for Rab27a were
investigated using MassArray genotyping in 133 UK
Caucasian patients with systemic-onset JIA and 384
ethnically matched unrelated control subjects. Addi-
tional control genotypes were accessed from the data
generated by the Wellcome Trust Case Control Consor-
tium.
Results. No significant association was found
between any SNP within the 4 selected loci and systemic-
onset JIA, by either single-point or haplotype analysis.
Conclusion. The results of this study demonstrate
that genes involved in HLH do not confer a significant
risk of association with systemic-onset JIA.
Systemic-onset juvenile idiopathic arthritis (JIA)
constitutes 10–20% of all cases of JIA (1) but accounts
for two-thirds of the mortality that occurs in these
patients (2). The major cause of mortality over the last
decade has been macrophage activation syndrome
(MAS) or hemophagocytic lymphohistiocytosis (HLH).
MAS is a severe, potentially life-threatening condition
characterized by the excessive activation of well-
differentiated macrophages. It results in fever, hepato-
splenomegaly, lymphadenopathy, severe cytopenia,
serious liver disease, coagulopathy, and neurologic in-
volvement. MAS is usually seen with systemic-onset JIA
and very rarely with the other subtypes of JIA (3,4).
A variety of triggers, including viral infections,
active systemic disease, and drugs, have been implicated
in the pathogenesis of MAS in patients with systemic-
onset JIA (3). The true incidence of MAS in this subtype
of JIA is not known. In one retrospective review of cases
from a tertiary institution, MAS developed in 7 (6.8%)
of the 103 children in whom systemic-onset JIA was
diagnosed over a 20-year period (5). Those investigators,
however, postulated that the true incidence of MAS
might have been much higher, since mild cases of MAS
are not always diagnosed. It is widely acknowledged by
many pediatric rheumatologists that subclinical MAS is
seen frequently (3,6,7). It has been speculated that MAS
and systemic-onset JIA are simply “different ends of the
same spectrum” (3,7). The presence of coagulation
abnormalities and greatly elevated serum ferritin levels,
both of which are characteristic features of MAS, in the
majority of patients with active systemic-onset JIA is
consistent with this idea.
It is increasingly recognized that MAS bears a
close resemblance to a histiocytic disorder, secondary
HLH, that is seen in a heterogeneous group of diseases,
including infections, neoplasms, hematologic conditions,
and autoimmune disorders (8). The current classifica-
tion of histiocytic disorders categorizes hemophagocytic
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869syndromes as either primary or secondary. Primary
HLH includes a clearly familial form and a sporadic
form without a clear family history that is nonetheless
thought to be genetic in origin. Secondary HLH is seen
in the context of a wide variety of conditions. Our 4
candidate genes were selected for investigation because,
in up to 50% of patients with primary HLH, the
underlying defect is caused by mutations in the genes
encoding for perforin (PRF1; 10q22) or UNC13 (Caeno-
rhabditis elegans homolog of D [UNC13D]; 17q25.1) (9).
Perforin is required to deliver granzyme B to target cells,
after which an apoptotic program is initiated, leading to
the demise of the target cells. Thus far, mutations within
the gene encoding for granzyme B (GZMB; 14q11.2)
have not been described in cases of HLH, but the
functional role of GZMB suggests it is a valid candidate
for genetic investigation. Finally, mutations in Ras-
associated protein Rab 27A (Rab27a; 15q21) have been
shown to play a causal role in the development of HLH
in patients with Griscelli syndrome (9).
In a study by Grom et al, natural killer (NK) cell
activity was shown to be low in patients with MAS (10).
Some of these patients also had low levels of perforin
expression, although genetic analysis did not identify the
mutations that had been subjected to screening. Re-
cently, NK cell dysfunction was investigated in a cohort
of patients with pauciarticular JIA, polyarticular JIA, or
systemic-onset JIA (11). The results of the study showed
that in patients with systemic-onset JIA who had not yet
had an episode of MAS, there was a decrease in NK cell
function, similar to that seen in HLH. In the present
study we therefore hypothesized that defective apoptosis
in patients with systemic-onset JIA could be due to
polymorphisms in the genes PRF1, GZMB, UNC13D,o r
Rab27a.
PATIENTS AND METHODS
Patients and controls. Blood samples were obtained
from all subjects following the provision of informed consent.
Ethics approval was obtained from the Multi-centre Research
Ethics Committee (MREC 99/8/84) and the University of
Manchester committee on the ethics of research on human
beings (8/92/[i][b]). DNA samples were collected from patients
with JIA as part of the British Society for Paediatric and
Adolescent Rheumatology national repository for JIA. The
diagnosis of JIA was classified according to the International
League of Associations for Rheumatology classification crite-
ria (12).
DNA samples from 133 UK Caucasian patients with
systemic-onset JIA were available for genotyping. A popula-
tion of unrelated and ethnically matched healthy individuals
(n  384) was used as the control group. All control subjects
either were blood donors or had been recruited via general
practitioner patient registries. In addition, genotyping data
were obtained from an additional 3,000 healthy UK Cauca-
sian subjects, who were studied as part of the Wellcome Trust
Case Control Consortium (WTCCC; for details see the
WTCCC Web site at http://www.wtccc.org.uk) (13); these data
were used as an additional control. This resource was searched
to identify overlap with the SNPs that had been genotyped or
to find perfect proxys (r
2  1) with the SNPs.
Genotyping. Haplotype-tagging SNPs were selected
from the HapMap database (on the HapMap Web site at
www.hapmap.org), and additional informative SNPs were se-
lected from the National Center for Biotechnology Informa-
tion (NCBI) SNP database (on the NCBI Web site at
www.ncbi.nlm.nih.gov/SNP). SNPs with a minor allele fre-
quency (MAF) of 10% were selected; these were in PRF1
(n  3), GZMB (n  5), UNC13D (n  7), and Rab27a (n 
11). In addition, the A91V change in the PRF1 gene was also
studied (14). Genotyping was performed using MassArray
high-throughput DNA analysis with matrix-assisted laser de-
sorption ionization–time-of-flight mass spectrometry (Seque-
nom, San Diego, CA). Amplifications were conducted accord-
ing to the manufacturer’s protocol. Polymerase chain reaction
primers and probe sequences are available from the corre-
sponding author upon request.
Statistical analysis. The raw data were “cleaned” prior
to analysis, which allowed us to remove DNA samples that
failed to genotype for 20% of the SNPs assayed, and also to
remove the SNPs that failed detection in 20% of samples.
Hardy-Weinberg equilibrium was determined using Stata ver-
sion 8 software (College Station, TX) in the case and control
groups separately. SNPs were removed from the analysis if
deviation from Hardy-Weinberg equilibrium (P  0.05) was
observed in the controls. Genotype counts in the control panel
from the WTCCC (n  2,938) were compared with those in
our own control group. In the case of nonsignificant differ-
ences between the control groups, data were combined, and
the total control population was compared with the patients
with systemic-onset JIA.
For single-point analysis, associations were investi-
gated by chi-square test or Fisher’s exact test, using Stata
version 8. P values less than or equal to 0.05 were considered
significant. For multipoint analysis, linkage disequilibrium
was calculated, and associations of varying-length haplotypes
were tested using the expectation-maximization algorithm.
This was implemented using HelixTree software (http://www.
goldenhelix.com/index.jsp).
This study had 80% power to detect an odds ratio of
2.0, at the 5% significance level, for all of the SNPs studied
except for the A91V change in PRF1, for which the study had
80% power to detect an odds ratio of 2.4, also at the 5%
significance level. These levels were determined using Quanto
software (http://hydra.usc.edu/GxE). Utilization of the
WTCCC control genotype data enhanced the study power for
certain SNPs (see Table 3), providing 82% power to detect an
odds ratio of 1.8, again at the 5% significance level.
RESULTS
Three SNPs, rs88581 (in PRF1), rs10873219 (in
GZMB), and rs11630859 (in Rab27a), deviated from
870 DONN ET ALHardy-Weinberg equilibrium in the controls, and were
therefore excluded from any further analysis. Our geno-
typing data for PRF1 captured 80% of the common
SNPs (MAF 0.05), with an r
2 value  0.8, that are
present in the phase II CEPH HapMap resource (listed
at www.hapmap.org). Similarly, the coverage was 88% of
the common SNPs for GZMB, 86% for UNC13D, and
97% for Rab27a.
The SNP genotype frequencies were compared
between the patients with systemic-onset JIA and our
control panel of healthy individuals. No significant asso-
ciations (P  0.05) were observed for any of the SNPs
(Tables 1 and 2). Furthermore, no significant asso-
ciations of haplotypes were seen for any of the loci
studied.
For 7 of the SNPs included in this study, geno-
typing information from an additional 2,938 control
subjects was available from the WTCCC (http://
www.wtccc.org.uk). No individual within our own con-
trol panel had been studied as part of the WTCCC.
None of the SNPs in this additional control group
deviated from Hardy-Weinberg equilibrium. There were
no statistically significant differences in the genotype
frequencies between our control panel and this large set
of control data for the 7 SNPs of interest. Therefore, the
control groups were combined for comparison of their
genotype frequencies with those found in the systemic-
onset JIA group. Despite the increased number of
controls, no SNP was found to be significantly associated
with systemic-onset JIA (Table 3).
DISCUSSION
Host survival depends on an immune system that
can protect against infectious pathogens and provide
control mechanisms that spare the host from immune
damage. The condition known as MAS comprises a set
of symptoms caused by the excessive activation and
Table 1. PRF1 and GZMB single-nucleotide polymorphism (SNP) genotype frequencies in patients with systemic-onset juvenile idiopathic arthritis
(JIA) and controls
SNP, genotype
Systemic-onset JIA Controls
P*
Total sample
size
Subjects with
genotype, no.
Frequency of
genotype, %
Total sample
size
Subjects with
genotyope, no.
Frequency of
genotype, %
PRF1
rs3758562 118 356
AA 55 46.6 166 46.6
AG 54 45.8 162 45.5
GG 9 7.6 28 7.9 0.99
A91V 107 329
CC 104 97.2 311 94.5
CT 2 1.9 17 5.2
TT 1 0.9 1 0.3 0.25†
rs885822 120 354
TT 40 33.3 130 36.7
TC 65 54.2 171 48.3
CC 15 12.5 53 15.0 0.55
GZMB
rs7144366 109 346
CC 38 34.9 132 38.1
CT 58 53.2 159 46.0
TT 13 11.9 55 15.9 0.36
rs8192917 118 359
AA 72 61.0 217 60.5
AG 40 33.9 130 36.2
GG 6 5.1 12 3.3 0.65
rs2236338 110 348
AA 69 62.7 213 61.2
AG 35 31.8 119 34.2
GG 6 5.5 16 4.6 0.86
rs2236337 119 357
TT 72 60.5 217 60.8
TC 40 33.6 127 35.6
CC 7 5.9 13 3.6 0.56
* By chi-square test.
† By Fisher’s exact test.
HLH GENES AND LACK OF ASSOCIATION WITH SYSTEMIC-ONSET JIA 871Table 2. UNC13D and Rab27a single-nucleotide polymorphism (SNP) genotype frequencies in patients with systemic-onset juvenile idiopathic
arthritis (JIA) and controls
SNP, genotype
Systemic-onset JIA Controls
P*
Total sample
size
Subjects with
genotype, no.
Frequency of
genotype, %
Total sample
size
Subjects with
genotype, no.
Frequency of
genotype, %
UNC13D
rs3744010 116 352
GG 63 54.3 215 61.1
GA 49 42.2 123 34.9
AA 4 3.5 14 4.0 0.39†
rs7223416 113 338
CC 58 51.3 191 56.5
CG 49 43.4 129 38.2
GG 6 5.3 18 5.3 0.61
rs3744026 119 357
TT 110 92.4 327 91.6
TC 9 7.6 30 8.4
CC 0 0 0 0 0.85†
rs17581728 117 354
CC 65 55.6 224 63.2
CT 48 41.0 117 33.1
TT 4 3.4 13 3.7 0.30†
rs2290768 120 354
CC 110 91.7 315 89.0
CT 10 8.3 39 11.0
TT 0 0 0 0 0.49†
rs2290769 116 357
CC 67 57.8 223 62.5
CG 46 39.7 121 33.9
GG 3 2.5 13 3.6 0.52†
rs7210574 116 348
TT 61 52.6 190 54.6
TC 46 39.7 132 37.9
CC 9 7.7 26 7.5 0.92
Rab27a
rs11629613 102 317
TT 78 76.5 246 77.6
TC 23 22.6 68 21.5
CC 1 0.9 3 0.9 0.95†
rs7167572 93 289
CC 31 33.3 119 41.2
CT 45 48.4 128 44.3
TT 17 18.3 42 14.5 0.63
rs11071175 120 357
AA 29 24.2 92 25.8
AG 66 55.0 181 50.7
GG 25 20.8 84 23.5 0.51
rs4261468 111 347
AA 68 61.3 203 58.5
AG 40 36.0 130 37.5
GG 3 2.7 14 4.0 0.23†
rs24444043 107 332
CC 30 28.0 100 30.1
CT 52 48.6 172 51.8
TT 25 23.4 60 18.1 0.44
rs2444039 117 353
GG 41 35.0 139 39.4
GT 61 52.1 178 50.4
TT 15 12.9 36 10.2 0.35
rs7181237 115 353
CC 73 63.5 196 55.5
CG 36 31.3 131 37.1
GG 6 5.2 26 7.4 0.26
872 DONN ET ALproliferation of T cells and well-differentiated macro-
phages. This activation is known to accompany the
presentation of systemic-onset JIA. In many such cases,
an overwhelming inflammatory reaction occurs, which
can be fatal. Clinically, MAS resembles secondary HLH.
Genes contributing to the pathogenesis of HLH
are beginning to be defined (9). We aimed to determine
whether any SNP within these key genes conferred an
increased risk of susceptibility to systemic-onset JIA. We
did not attempt to study a population of patients with
systemic-onset JIA having a known history of MAS.
Such a patient population would be useful to examine
genetically. However, collection of such a cohort would
require collaboration with multiple centers worldwide,
and there is the possibility that the numbers of patients
involved would still be small and of limited informative
value for genetic association studies. Furthermore, we
do not know which, if any, of the patients with systemic-
onset JIA included in the present study experienced
MAS. Instead, we attempted to determine whether there
is a shared genetic basis between MAS/HLH and
systemic-onset JIA per se, recognizing that other genes
and as yet unidentified environmental triggers are also
required for the expression of the systemic-onset JIA
phenotype.
No association was seen for any of the SNPs in
each of the 4 genes considered. This remained the case
despite our attempt to increase the study power by
accessing additional control genotype data. We can
therefore conclude that these SNPs do not contribute a
substantial risk of susceptibility to systemic-onset JIA.
Increasingly, it is becoming apparent that for complex
conditions such as systemic-onset JIA, the proportional
risk at any one locus is small, with odds ratios substan-
tially lower than 1.8 becoming the norm (15). In this
respect, our study remains underpowered. However, it
does represent one of the largest systemic-onset JIA
cohorts available for genetic investigation, and our study
Table 3. PRF1, GZMB, UNC13D, and Rab27a single-nucleotide polymorphisms (SNPs) in patients with systemic-onset juvenile idiopathic arthritis
(JIA) and combined controls*
Gene, SNP
Perfect proxy SNP
(r
2  1)
Systemic-onset JIA Combined controls
P 1,1 1,2 2,2 1,1 1,2 2,2
PRF1, rs3758562 rs1099427 55 (46.6) 54 (45.8) 9 (7.6) 1,501 (45.9) 1,466 (44.8) 304 (9.3) 0.87
GZMB, rs8192917 rs10909625 72 (61.0) 40 (33.9) 6 (5.1) 1,968 (59.7) 1,141 (34.7) 185 (5.6) 0.95
UNC13d, rs7223416 rs8067076 58 (51.3) 49 (43.4) 6 (5.3) 1,442 (45.2) 1,438 (45.0) 313 (9.8) 0.19
Rab27a
rs11071175 rs8032594 29 (24.2) 66 (55.0) 25 (20.8) 890 (27.1) 1,672 (50.9) 722 (22.0) 0.60
rs2444039 Original SNP in WTCCC 41 (35.0) 61 (52.2) 15 (12.8) 1,275 (38.7) 1,541 (46.9) 473 (14.4) 0.53
rs1050931 rs7165491 80 (72.1) 28 (25.2) 3 (2.7) 2,094 (63.7) 1,063 (32.3) 133 (4.0) 0.19
rs1061824 rs7165491 81 (68.1) 35 (29.4) 3 (2.5) 2,097 (63.6) 1,067 (32.4) 132 (4.0) 0.52
* Values are the no. (%) of subjects. 1  wild-type allele; WTCCC  Wellcome Trust Case Control Consortium.
Table 2. (Cont’d)
SNP, genotype
Systemic-onset JIA Controls
P*
Total sample
size
Subjects with
genotype, no.
Frequency of
genotype, %
Total sample
size
Subjects with
genotype, no.
Frequency of
genotype, %
rs9920165 114 349
AA 92 80.7 276 79.1
AG 26 17.5 71 20.3
GG 2 1.8 2 0.6 0.11†
rs1050931 111 353
CC 80 72.1 224 63.5
CT 28 25.2 116 32.9
TT 3 2.7 13 3.6 0.20†
rs1061824 119 359
AA 81 68.1 227 63.2
AG 35 29.4 120 33.4
GG 3 2.5 12 3.4 0.20†
* By chi-square test.
† By Fisher’s exact test.
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and functional outcomes.
In conclusion, we could not detect an association
between SNPs in PRF1, GZMB, UN13D,o rRab27a and
an increased risk of susceptibility to systemic-onset JIA.
Further studies, in larger cohorts of patients with
systemic-onset JIA, are required to evaluate whether
these genes contribute a more subtle risk of disease
susceptibility than could be determined from this study.
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